|
Wednesday, May 21, 2008 5:00am — PHARMA, BIOTECH & CHEM IP STRATEGY New Article - pharmaceutical polymorphs & patent strategyPolymorphs have been a key component of the pharmaceutical patent war for quite some time. Our latest article takes a brief look at the issues and summarises Duncan's presentation on 21 May at the Australian Generic Medicines Association conference in Sydney. Let me know what you think. Post a Comment | Permalink | + del.icio.us 2 CommentsDuncan saidThanks Kate. Here's a link to a decision from the Scottish Court of Session which held that a claim to a polymorph of Tibolone with a certain purity was not obvious: Arrow Generics Ltd v Akzo NB (represented in Scotland by Organon Laboratories Ltd), [2008] CSIH31 Thanks to IPKat for the link. posted on Sunday, May 25, 2008 5:57pm 0 Trackbackstrackback url: http://duncanbucknell.com/trackback.php?id=340 |
 
|
Kate Beattie said
http://vicbar.com.au/c.1.3.aspx?RollNumber=3984
Duncan, re your recent article, as you may be aware, Pumfrey J expressed some thoughts about the validity of a patent for a crystalline form of clarithromycin in Abbott v Ranbaxy and others [2004] EWHC 2723 (decision of Mr. Justice Pumfrey of 19 November 2004). The patent was held to be invalid at an interlocutory stage – but for reasons other than the lack of novelty of a crystalline form patent (which, he suggested, could be novel)
posted on Thursday, May 22, 2008 8:27am